Nasba Technology: Isothermal RNA Amplification in Qualitative and Quantitative Diagnostics

Romano, Joseph; Williams, Kimberly G.; Shurtliff, Roxanne N.; Ginocchio, Christine C.; Kaplan, Mark H.

doi:10.3109/08820139709048912

Cited by 76 publications

(51 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We therefore developed a real-time NASBA to quantitatively monitor the mRNAs of stem cell marker CD133 and the pan-endothelial cell marker CD146 in the mononuclear fraction of cancer patients. NASBA is a 96-well -based method of nucleic acid amplification highly receptive to standardization and currently a Food and Drug Administration -approved method to determine viral load in HIV-1 -infected patients (35,36,40). We show that CD133 mRNA expression is increased in patients with metastasis, more specifically bone metastasis, independent of primary tumor type.…”

Section: Discussionmentioning

confidence: 81%

Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases

Mehra¹,

Penning²,

Maas³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: We examined whether RNA expression of CD133, a surface molecule expressed on progenitors from hematopoietic and endothelial lineages, and CD146, a pan-endothelial marker, are increased in the blood of cancer patients and whether these factors correlate with patient characteristics and are predictive factors of survival. Experimental Design: We developed a real-time quantification method (nuclear acid sequence-based amplification) to determine expression of CD146 and CD133 mRNA in the peripheral blood mononuclear cells of 131 progressive cancer patients, 37 healthy volunteers, and 5 patients who received granulocyte colony-stimulating factor. Overall survival and other clinicopathologic variables were obtained. Cox proportional hazards studies were done. Results: We show that patients with metastatic disease have a significant increase in CD133 mRNA (P = 0.03), specifically patients with bone metastasis (P < 0.001). Cancer patients with high CD133 mRNA expression, using a defined cutoff value, show a decreased survival compared with patients with low or undetectable CD133 expression (21% versus 45% cumulative survival, respectively, after 20 months; P = 0.01). Among patients with metastasis to the bone, cumulative survival was 22%, compared with 61% for patients with high or low CD133 levels (P = 0.004). Multivariate analysis showed that CD133 expression is an independent predictor for overall survival in patients with bone metastases. CD146 mRNA was not increased in patients with cancer, nor did it correlate with clinical variables or survival. Conclusion: CD133, but not CD146, mRNA expression is increased in cancer patients with metastatic disease, specifically with bone metastasis. In addition, CD133 mRNA expression seems to be an independent prognostic factor for overall survival.

show abstract

Section: Discussionmentioning

confidence: 81%

Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases

Mehra¹,

Penning²,

Maas³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Various concentrations of synthetic RNAs derived from the cDNA sequence of MIP-1 ␣ and RANTES were used as internal standards in the reaction. Signal was detected after hybridization with a ruteniumlabeled probe and quantified by measuring chemiluminiscence (26). The primer pairs and probes are described elsewhere (Romano, J.W., R.N.…”

Section: Methodsmentioning

confidence: 99%

Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro.

Oliva¹,

Kinter²,

Vaccarezza³

et al. 1998

J. Clin. Invest.

254

170

View full text Add to dashboard Cite

“…The monkeys were challenged by intrarectal exposure to 30 mucosal infectious doses of SIV mac251 challenge stock. SIV mac251 RNA in plasma was quantified by nucleic acid sequence-based amplification (60). Data describing the immunization and challenge of animals in groups 1B and 4 were published previously (8,9).…”

Section: Animals Immunizations and Challengementioning

confidence: 99%

Improved Vaccine Protection from Simian AIDS by the Addition of Nonstructural Simian Immunodeficiency Virus Genes

Hel

Tsai

Tryniszewska

et al. 2006

The Journal of Immunology

View full text Add to dashboard Cite

An HIV-1 vaccine able to induce broad CD4+ and CD8+ T cell responses may provide long-term control of viral replication. In this study we directly assess the relative benefit of immunization with vaccines expressing three structural Ags (Gag, Pol, and Env), three early regulatory proteins (Rev, Tat, and Nef), or a complex vaccine expressing all six Ags. The simultaneous administration of all six Ags during vaccination resulted in Ag competition manifested by a relative reduction of CD8+ T cell and lymphoproliferative responses to individual Ags. Despite the Ag competition, vaccination with all six Ags resulted in a delay in the onset and a decrease in the extent of acute viremia after mucosal challenge exposure to highly pathogenic SIVmac251. Reduced levels of acute viremia correlated with lower post-set point viremia and long-term control of infection. In immunized animals, virus-specific CD4+ T cell and lymphoproliferative responses were preserved during acute viremia, and the maintenance of these responses predicted the long-term virological outcome. Taken together, these results suggest that the breadth of the immune response is probably more important than high frequency responses to a limited number of epitopes. These data provide the first clear evidence of the importance of nonstructural HIV Ags as components of an HIV-1 vaccine.

show abstract

Nasba Technology: Isothermal RNA Amplification in Qualitative and Quantitative Diagnostics

Cited by 76 publications

References 12 publications

Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases

Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases

Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro.

Improved Vaccine Protection from Simian AIDS by the Addition of Nonstructural Simian Immunodeficiency Virus Genes

Contact Info

Product

Resources

About